Biopact on Equifund CFP

PATENTED TECHNOLOGY THAT MAKES FIGHTING DISEASE SIMPLER, FASTER AND CHEAPER.

Raise to date: $188,867

Reporting Date: 07/05/2020

Key Stats

Minimum Raise

$20,000

Maximum Raise

$1,070,000

Likelihood of Max Unlikely
Start Date

02/26/2020

Stop Date

02/12/2021

Days Remaining

219

Security Type

Common Stock

Investment Minimum

$465

Deal Type

Deal to Watch


Investment Summary

Status

Active

# of Investors

187

% of Minimum Raised

944%

% of Maximum Raised

18%

Dollars Per Day to Reach Max

$4,023

DPD* Committed

$1,453

DPD* Category

$0

DPD* All Companies

$2,176

Kingscrowd Momentum

$188,867

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Biopact Cellular Transport, with a valuation of $30 million, is raising funds on Equifund Crowd Funding Platform. The company has a unique patented intracellular delivery technology that transports gene-editing technologies to cells effectively, safely, and affordably. The delivery mechanism of Biopact Cellular Transport will help reduce the cost and increase the effectiveness of therapies like CRISPR, TALEN, and CAR-T. Biopact Cellular Transport was founded by Kurt Swogger and is led by Randy Kinsel as the President. The current crowdfunding round of the company has a minimum target of $20,000 and a maximum target of $1,070,000. Biopact Cellular Transport’s MGMR technology is protected by 77 patents worldwide and has the potential to revolutionize cellular medicines.

Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Biopact on Equifund CFP
Follow company
Follow Biopact on Equifund CFP
INVEST NOW

Get access to the first and only premium analytics and rating platform that enables informed startup investments.

Become an Informed Investor